摘要
目的探讨趋化因子受体CXCR4及其配体CXCL12在原发中枢神经系统淋巴瘤中的表达水平,分析它们在原发中枢神经系统淋巴瘤的发生、发展过程中的可能作用。方法采用免疫组化EnVision二步法检测CXCR4及CXCL12在5例原发中枢神经系统淋巴瘤、10例正常脑组织细胞中的表达。采用半定量RT-PCR检测CXCR4和CXCL12在5例原发中枢神经系统淋巴瘤以及正常脑组织中的表达情况。结果免疫组化EnVision二步法:CXCR4在肿瘤标本中阳性表达率为100%(5/5),在正常脑组织标本中阳性表达率为0%(0/10);CXCL12在肿瘤标本中阳性表达率为100%(5/5),在正常脑组织标本中阳性表达率为100%(10/10)。半定量RT-PCR法检测标本中的CXCR4、CXCL12显示:在肿瘤标本中全部检出,而在正常脑组织标本中仅检出CXCL12的表达。结论 CXCR4/CXCL12信号通路在原发中枢神经系统淋巴瘤的发生、发展过程中起作用。
Objective To elucidate the relationship of the expression of ehemokine receptor CXCR4 and its ligand CXCL12 in 5 cases of primary central nervous system lymphomas（PCNSL） and their clinical significance. Method The expression of chemokine receptor and its ligand in 5 cases of PCNSL and 10 normal brain tissues were investigated using immunohistochemieal and reverse transcription polymerase chain reaction（RT-PCR） methods. Results Immunohistoehemistry：Of the 5 PCNSLs, all specimens （100%） were positive for CXCR4 and CXCL12. Of the 10 normal brain tissues, all specimens （100%） were positive for CXCL12, and none was positive for CXCR4. RT- PCR：Of the PCNSLs, all specimens expressed the RNA of CXCR4 and CXCL12. The specimens of normal brain tissue was only expressed the RNA of CXCL12. Conclusion Chemokine receptor CXCR4 and its ligand CXCL12 play important roles in the pathogenesis of primary central nervous system lymphoma.
出处
《临床神经外科杂志》
CAS
2011年第6期285-287,共3页
Journal of Clinical Neurosurgery
基金
江苏省"科教兴卫工程"医学重点学科基金(XK200722)
